Article
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Genome medicine - 31 May 2021
Tsui Dana W Y, Cheng Michael L, Shady Maha, Yang Julie L, Stephens Dennis, Won Helen, Srinivasan Preethi, Huberman Kety, Meng Fanli, Jing Xiaohong, Patel Juber, Hasan Maysun, Johnson Ian, Gedvilaite Erika, Houck-Loomis Brian, Socci Nicholas D, Selcuklu S Duygu, Seshan Venkatraman E, Zhang Hongxin, Chakravarty Debyani, Zehir Ahmet, Benayed Ryma, Arcila Maria, Ladanyi Marc, Funt Samuel A, Feldman Darren R, Li Bob T, Razavi Pedram, Rosenberg Jonathan, Bajorin Dean, Iyer Gopa, Abida Wassim, Scher Howard I, Rathkopf Dana, Viale Agnes, Berger Michael F, Solit David B
Abstract excerpt
BACKGROUND: Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulating DNA in plasma that is tumor-derived (i.e., cfDNA tumor fraction). We hypothesized that cfDNA tumor fraction could inform the interpretation of negative cfDNA results and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.